Quantcast
Home > Quotes > PTN

Palatin Technologies, Inc. Common Stock (PTN) Quote & Summary Data

PTN 
$0.7099
*  
0.0089
1.27%
Get PTN Alerts
*Delayed - data as of Jan. 22, 2019  -  Find a broker to begin trading PTN now
Exchange:AMEX
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
3.875
Today's High / Low
$ 0.71 / $ 0.69
Share Volume
630,759
90 Day Avg. Daily Volume
900,447
Previous Close
$ 0.701
52 Week High / Low
$ 1.59 / $ 0.59
Market Cap
144,154,728
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.17

Intraday Chart

Shares Traded

Share Volume:
630,759
90 Day Avg. Daily Volume:
900,447

P/E Ratio

P/E Ratio:
17.75
Forward P/E (1y):
Earnings Per Share (EPS):
$ 0.04

Trading Range

The current last sale of $0.7099 is 20.32% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.71 $ 1.59
 Low: $ 0.69 $ 0.59

Company Description (as filed with the SEC)

We are a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Our most advanced product candidate is Vyleesi(TM), the trade name for bremelanotide, a peptide melanocortin receptor 4 (MC4r) agonist, for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder ("HSDD"), which is a type of female sexual dysfunction ("FSD"), defined as low desire with associated distress or interpersonal difficulty. A New Drug Application ("NDA") has been submitted to the U.S. Food and Drug Administration ("FDA") by our exclusive North American licensee, AMAG Pharmaceuticals, Inc.  ... More ...  


Risk Grade

Where does PTN fit in the risk graph?


Risk Grade Scale

Consensus Recommendation

Analyst Info